New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) show that two long-acting injectable PrEP options, lenacapavir and cabotegravir, are safe, well tolerated and effective for use during pregnancy and breastfeeding. Both drugs showed minimal transfer to infants through breast milk and no increase in adverse pregnancy or birth outcomes, supporting their use as convenient HIV prevention options for pregnant and lactating people at risk of HIV.
Read the full news story at aidsmap.
All aidsmap reports from IAS 2025 can be accessed here.
Source : aidsmap
Related HIV and Co-Infections News
-
OHSU awarded $6.7 million to study effects of cannabis use during pregnancy in people with HIV
-
Mungo awarded $2.5M for research project to improve HPV treatment outcomes for women living with HIV
-
Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.